DUBLIN–(BUSINESS WIRE)–The “Clinical Trial Agreements: Key Legal, Regulatory and IP (Intellectual Property) Considerations for the EU (European Union) and UK MarketsDUBLIN–(BUSINESS WIRE)–The “Clinical Trial Agreements: Key Legal, Regulatory and IP (Intellectual Property) Considerations for the EU (European Union) and UK Markets

1 Day Clinical Trial Agreements Training Course: Key Legal, Regulatory and IP (Intellectual Property) Considerations for the EU (European Union) and UK Markets (Mar 18, 2026) – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Clinical Trial Agreements: Key Legal, Regulatory and IP (Intellectual Property) Considerations for the EU (European Union) and UK Markets Training Course (Mar 18, 2026)” training has been added to ResearchAndMarkets.com’s offering.

The life sciences sector is heavily regulated and CTAs are some of the most important agreements for companies operating in this sector. Having appropriate CTAs in place is therefore essential for managing relationships between the different stakeholders, and apportioning risk and responsibilities between them. If appropriate contractual arrangements are not in place, a clinical trial may not receive approval or issues may arise with the integrity or validity of the data collected. Further, disputes between the parties can arise if responsibilities are not clearly defined in the agreement.

This intensive short course provides essential insights into the legal framework governing clinical trials in the EU and UK, ensuring compliance, protecting intellectual property and managing liability risks.

The expert speakers will explain the dynamic and increasingly demanding regulatory and data protection landscape to better inform those negotiations and drafting these agreements.

Benefits of attending

By attending this seminar you will:

  • Learn about the regulatory framework concerning clinical trials in the EU and the UK
  • Understand the EU Clinical Trial Regulation and UK Human Use (Clinical Trials) (Amendment) Regulations 2024
  • Examine the roles and obligations of stakeholders including sponsors, CROs, investigators, and ethics committees
  • Navigate clinical trials approval, ethical approvals, policy issues, and the legal risks of non-compliance
  • Master informed consent, clinical trial transparency, and compensation models to mitigate legal exposure
  • Learn how to protect IP rights in clinical trials, draft strong confidentiality agreements, and manage publication clauses.

Who Should Attend:

This course has been specially designed for:

  • Lawyers and in-house legal teams
  • Contract managers
  • Clinical contract specialists
  • Clinical trial managers and professionals
  • R&D staff
  • Regulatory specialists
  • And CROs, sponsors and healthcare organisations looking to stay ahead in an evolving legal landscape.

Key Topics Covered:

Overview of the regulation of clinical trials – the legal framework governing clinical trials in the EU and the UK

  • What a clinical trial is and the types of clinical trials
  • Who the stakeholders are and their roles and obligations
  • EU regulatory framework under the Clinical Trial Regulation 536/2014/EU and the Clinical Trials Information System (CTIS)
  • UK framework post Brexit under the Human Use (Clinical Trials) (Amendment) Regulations 2024
  • Clinical trial approval, ethics approval and policy issues (eg Health Research Authority approval)
  • What could happen if a clinical trial is not conducted in accordance with the law

Consent, data and IP rights

Sponsors and CROs must meet obligations relating to transparency, participant consent and data protection in clinical trials. In turn, those obligations have an impact on parties’ liability risks and IP rights. This session will examine:

  • Participant consent and liability risks:
    • Transparency obligations and the publication of clinical trials outcomes
    • How transparency and consent interact with liability risks, including:
      • Compensation models
      • Clinical trials insurance
      • Product liability risks for licensed products
  • Data protection:
    • Overview of the requirements
    • Use of patient data during and after a clinical trial (particularly in light of the 3/2019 guidance from the European Data Protection Board)
  • Intellectual property rights:
    • Relevant IP rights associated with clinical trials
    • How to best protect any accruing IP rights
    • Drafting and negotiating of IP rights, confidentiality and publication clauses

Final questions

For more information about this training visit https://www.researchandmarkets.com/r/6n17d8

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Market Opportunity
1 Logo
1 Price(1)
$0.008365
$0.008365$0.008365
+6.69%
USD
1 (1) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Hoskinson Says XRP and Cardano Projects Lead Tokenization Race

Hoskinson Says XRP and Cardano Projects Lead Tokenization Race

Cardano founder Charles Hoskinson says Web3-native platforms already operate at a scale traditional finance has yet to reach. Cardano founder Charles Hoskinson
Share
LiveBitcoinNews2025/12/27 07:59
Sharplink CEO: Stablecoins, RWA, and sovereign wealth funds will drive Ethereum's TVL to grow tenfold by 2026.

Sharplink CEO: Stablecoins, RWA, and sovereign wealth funds will drive Ethereum's TVL to grow tenfold by 2026.

PANews reported on December 27 that Sharplink CEO Joseph Chalom stated that the surge in stablecoins, tokenized RWAs, and the growing interest from sovereign wealth
Share
PANews2025/12/27 08:15
Best Crypto to Buy as Saylor & Crypto Execs Meet in US Treasury Council

Best Crypto to Buy as Saylor & Crypto Execs Meet in US Treasury Council

The post Best Crypto to Buy as Saylor & Crypto Execs Meet in US Treasury Council appeared on BitcoinEthereumNews.com. Michael Saylor and a group of crypto executives met in Washington, D.C. yesterday to push for the Strategic Bitcoin Reserve Bill (the BITCOIN Act), which would see the U.S. acquire up to 1M $BTC over five years. With Bitcoin being positioned yet again as a cornerstone of national monetary policy, many investors are turning their eyes to projects that lean into this narrative – altcoins, meme coins, and presales that could ride on the same wave. Read on for three of the best crypto projects that seem especially well‐suited to benefit from this macro shift:  Bitcoin Hyper, Best Wallet Token, and Remittix. These projects stand out for having a strong use case and high adoption potential, especially given the push for a U.S. Bitcoin reserve.   Why the Bitcoin Reserve Bill Matters for Crypto Markets The strategic Bitcoin Reserve Bill could mark a turning point for the U.S. approach to digital assets. The proposal would see America build a long-term Bitcoin reserve by acquiring up to one million $BTC over five years. To make this happen, lawmakers are exploring creative funding methods such as revaluing old gold certificates. The plan also leans on confiscated Bitcoin already held by the government, worth an estimated $15–20B. This isn’t just a headline for policy wonks. It signals that Bitcoin is moving from the margins into the core of financial strategy. Industry figures like Michael Saylor, Senator Cynthia Lummis, and Marathon Digital’s Fred Thiel are all backing the bill. They see Bitcoin not just as an investment, but as a hedge against systemic risks. For the wider crypto market, this opens the door for projects tied to Bitcoin and the infrastructure that supports it. 1. Bitcoin Hyper ($HYPER) – Turning Bitcoin Into More Than Just Digital Gold The U.S. may soon treat Bitcoin as…
Share
BitcoinEthereumNews2025/09/18 00:27